CTEP 2013 Fall Early Drug Development Survey

 
1. As a result of participating in this CME activity, do you agree that you can:
Strongly DisagreeDisagreeNot SureAgreeStrongly Agree
Attendees at the meeting will need to understand information from ongoing Phase I trials, specifically data on new investigational agents that are in the early stages of clinical investigation, emerging toxicity and efficacy data as well as pharmacokinetics and translational studies designed to identify target engagement. This meeting agenda includes a session of presentations on phase I trials that will address some of these information gaps for practicing clinicians and clinical investigation team members.
Attendees at the meeting will need to understand results from ongoing CTEP- sponsored Phase II trials, specifically data on investigational agents that are being evaluated in phase II trials, emerging efficacy data and long-term toxicity as well as pharmacokinetics and translational studies designed to identify predictive and prognostic markers. This meeting agenda includes a session of presentations on phase II trials that will address some of these information gaps for practicing clinicians and clinical investigation team members.
Meeting attendees will learn about new antibody immunoconjugate investigational therapies being developed for the treatment of hematologic malignancies and solid tumors. The meeting will include a session of presentations on clinical development programs for some of the most promising antibody-directed therapies now in the clinic.
Clinicians attending this meeting have prioritized epigenetic therapies as an area of significant promise. A session at this meeting is being organized to introduce attendees to the emerging scientific findings in the field of epigenetics and how these developments will inform new therapies for cancer. This session of epigenetic biology and new cancer therapies targeted at epigenetic processes will provide a comprehensive review.
2. We would like to know if participating in this CME activity will contribute to changes you may make in your approaches to managing patients in your practice. Do you anticipate changing something you currently do in your practice or doing something new as a result of your participation in this CME activity?
3. Do you agree that E. Anders Kolb:
Strongly DisagreeDisagreeNot SureAgreeStrongly Agree
a. provided information that was relevant to my practice circumstances?
b. provided an opportunity for questions and discussion?
c. made a presentation that was well balanced, supported by scientific information, and provided a fair description of all therapeutic options?
4. Do you agree that Brigitte Widemann:
Strongly DisagreeDisagreeNot SureAgreeStrongly Agree
a. provided information that was relevant to my practice circumstances?
b. provided an opportunity for questions and discussion?
c. made a presentation that was well balanced, supported by scientific information, and provided a fair description of all therapeutic options?
5. Do you agree that Anu Banerjee:
Strongly DisagreeDisagreeNot SureAgreeStrongly Agree
a. provided information that was relevant to my practice circumstances?
b. provided an opportunity for questions and discussion?
c. made a presentation that was well balanced, supported by scientific information, and provided a fair description of all therapeutic options?
6. Do you agree that David Quinn:
Strongly DisagreeDisagreeNot SureAgreeStrongly Agree
a. provided information that was relevant to my practice circumstances?
b. provided an opportunity for questions and discussion?
c. made a presentation that was well balanced, supported by scientific information, and provided a fair description of all therapeutic options?
7. Do you agree that Danielle Jandial:
Strongly DisagreeDisagreeNot SureAgreeStrongly Agree
a. provided information that was relevant to my practice circumstances?
b. provided an opportunity for questions and discussion?
c. made a presentation that was well balanced, supported by scientific information, and provided a fair description of all therapeutic options?
8. Do you agree that Giuseppe Giaccone:
Strongly DisagreeDisagreeNot SureAgreeStrongly Agree
a. provided information that was relevant to my practice circumstances?
b. provided an opportunity for questions and discussion?
c. made a presentation that was well balanced, supported by scientific information, and provided a fair description of all therapeutic options?
9. Do you agree that Chandra Belani:
Strongly DisagreeDisagreeNot SureAgreeStrongly Agree
a. provided information that was relevant to my practice circumstances?
b. provided an opportunity for questions and discussion?
c. made a presentation that was well balanced, supported by scientific information, and provided a fair description of all therapeutic options?
10. Do you agree that Christine Chung:
Strongly DisagreeDisagreeNot SureAgreeStrongly Agree
a. provided information that was relevant to my practice circumstances?
b. provided an opportunity for questions and discussion?
c. made a presentation that was well balanced, supported by scientific information, and provided a fair description of all therapeutic options?
11. Do you agree that Paul Barr:
Strongly DisagreeDisagreeNot SureAgreeStrongly Agree
a. provided information that was relevant to my practice circumstances?
b. provided an opportunity for questions and discussion?
c. made a presentation that was well balanced, supported by scientific information, and provided a fair description of all therapeutic options?
12. Do you agree that George Somlo:
Strongly DisagreeDisagreeNot SureAgreeStrongly Agree
a. provided information that was relevant to my practice circumstances?
b. provided an opportunity for questions and discussion?
c. made a presentation that was well balanced, supported by scientific information, and provided a fair description of all therapeutic options?
13. Do you agree that Jonathan Drachman:
Strongly DisagreeDisagreeNot SureAgreeStrongly Agree
a. provided information that was relevant to my practice circumstances?
b. provided an opportunity for questions and discussion?
c. made a presentation that was well balanced, supported by scientific information, and provided a fair description of all therapeutic options?
14. Do you agree that Howard Burris:
Strongly DisagreeDisagreeNot SureAgreeStrongly Agree
a. provided information that was relevant to my practice circumstances?
b. provided an opportunity for questions and discussion?
c. made a presentation that was well balanced, supported by scientific information, and provided a fair description of all therapeutic options?
15. Do you agree that Tom Davis:
Strongly DisagreeDisagreeNot SureAgreeStrongly Agree
a. provided information that was relevant to my practice circumstances?
b. provided an opportunity for questions and discussion?
c. made a presentation that was well balanced, supported by scientific information, and provided a fair description of all therapeutic options?
16. Do you agree that Ira Pastan:
Strongly DisagreeDisagreeNot SureAgreeStrongly Agree
a. provided information that was relevant to my practice circumstances?
b. provided an opportunity for questions and discussion?
c. made a presentation that was well balanced, supported by scientific information, and provided a fair description of all therapeutic options?
17. Do you agree that Stanley Frankel:
Strongly DisagreeDisagreeNot SureAgreeStrongly Agree
a. provided information that was relevant to my practice circumstances?
b. provided an opportunity for questions and discussion?
c. made a presentation that was well balanced, supported by scientific information, and provided a fair description of all therapeutic options?
18. Do you agree that Sandra A. Mitchell & Ethan Basch:
Strongly DisagreeDisagreeNot SureAgreeStrongly Agree
a. provided information that was relevant to my practice circumstances?
b. provided an opportunity for questions and discussion?
c. made a presentation that was well balanced, supported by scientific information, and provided a fair description of all therapeutic options?
19. Do you agree that Jonathan Licht:
Strongly DisagreeDisagreeNot SureAgreeStrongly Agree
a. provided information that was relevant to my practice circumstances?
b. provided an opportunity for questions and discussion?
c. made a presentation that was well balanced, supported by scientific information, and provided a fair description of all therapeutic options?
20. Do you agree that Scott Armstrong:
Strongly DisagreeDisagreeNot SureAgreeStrongly Agree
a. provided information that was relevant to my practice circumstances?
b. provided an opportunity for questions and discussion?
c. made a presentation that was well balanced, supported by scientific information, and provided a fair description of all therapeutic options?
21. Do you agree that Stephen Baylin:
Strongly DisagreeDisagreeNot SureAgreeStrongly Agree
a. provided information that was relevant to my practice circumstances?
b. provided an opportunity for questions and discussion?
c. made a presentation that was well balanced, supported by scientific information, and provided a fair description of all therapeutic options?
22. Do you agree that Peter Tummino:
Strongly DisagreeDisagreeNot SureAgreeStrongly Agree
a. provided information that was relevant to my practice circumstances?
b. provided an opportunity for questions and discussion?
c. made a presentation that was well balanced, supported by scientific information, and provided a fair description of all therapeutic options?
23. Do you agree that Heike Keilhack:
Strongly DisagreeDisagreeNot SureAgreeStrongly Agree
a. provided information that was relevant to my practice circumstances?
b. provided an opportunity for questions and discussion?
c. made a presentation that was well balanced, supported by scientific information, and provided a fair description of all therapeutic options?
24. Do you agree that Craig Thompson:
Strongly DisagreeDisagreeNot SureAgreeStrongly Agree
a. provided information that was relevant to my practice circumstances?
b. provided an opportunity for questions and discussion?
c. made a presentation that was well balanced, supported by scientific information, and provided a fair description of all therapeutic options?
25. The Division of CME at the University of Arizona College of Medicine adheres to ACCME Standards regarding industry support of continuing medical education, and disclosure of faculty and commercial support relationships. Please assess our performance in this area by responding to the following questions.
YesNoN/A
a. Were you made aware that this CME course received (or did not receive) support from commercial firms that produce health care products?
b. Were you informed about the financial relationships of speaker(s) with companies that make products or provide services related to the content of tonight’s presentation?
Or that a speaker(s) had no financial relationships? Examples include honoraria, research grants, and stock ownership.
c. Did you experience any inappropriate selling pressure by representatives of commercial firms present at this course?
d. If a speaker mentioned off-label or experimental uses of drugs or devices, did they inform the audience that the uses of the drugs and/or devices mentioned were either experimental or had not been approved by the FDA for the use described?
26. EDD meeting organizers would like to solicit your suggestions for future sessions/topics/presenters at the meeting. Several topics have been suggested recently and are listed below. Please indicate your interest in having the following topics as part of future meetings:
27. Please list any other session topics including: specific tumor therapy sessions, sessions on specific drug classes, new targets for cancer therapeutics, keynote speakers.
28. General Comments
Powered by SurveyMonkey
Check out our sample surveys and create your own now!